Alibaba Health Information Technology Yönetim
Yönetim kriter kontrolleri 2/4
Alibaba Health Information Technology CEO'su Difan Shen, Nov2023 tarihinde atandı, in görev süresi 3.08 yıldır. in toplam yıllık tazminatı CN¥ 6.81M olup, şirket hissesi ve opsiyonları dahil olmak üzere 25.2% maaş ve 74.8% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.009% ine doğrudan sahiptir ve bu hisseler HK$ 6.21M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.3 yıl ve 2.3 yıldır.
Anahtar bilgiler
Difan Shen
İcra Kurulu Başkanı
CN¥6.8m
Toplam tazminat
| CEO maaş yüzdesi | 25.2% |
| CEO görev süresi | less than a year |
| CEO sahipliği | 0.009% |
| Yönetim ortalama görev süresi | 2.3yrs |
| Yönetim Kurulu ortalama görev süresi | 2.3yrs |
Son yönetim güncellemeleri
Recent updates
Earnings Tell The Story For Alibaba Health Information Technology Limited (HKG:241) As Its Stock Soars 30%
Oct 18
What Does Alibaba Health Information Technology Limited's (HKG:241) Share Price Indicate?
Sep 23Alibaba Health Information Technology (HKG:241) Is Looking To Continue Growing Its Returns On Capital
Jul 03After Leaping 26% Alibaba Health Information Technology Limited (HKG:241) Shares Are Not Flying Under The Radar
Jun 07Alibaba Health Information Technology's (HKG:241) Solid Earnings Are Supported By Other Strong Factors
Jun 06Risks Still Elevated At These Prices As Alibaba Health Information Technology Limited (HKG:241) Shares Dive 26%
Apr 21Is Now The Time To Look At Buying Alibaba Health Information Technology Limited (HKG:241)?
Apr 16Alibaba Health Information Technology (HKG:241) Might Have The Makings Of A Multi-Bagger
Mar 29Is There An Opportunity With Alibaba Health Information Technology Limited's (HKG:241) 36% Undervaluation?
Mar 12With A 25% Price Drop For Alibaba Health Information Technology Limited (HKG:241) You'll Still Get What You Pay For
Jan 17Is Now An Opportune Moment To Examine Alibaba Health Information Technology Limited (HKG:241)?
Jan 07Returns On Capital Are Showing Encouraging Signs At Alibaba Health Information Technology (HKG:241)
Dec 15Shareholders Should Be Pleased With Alibaba Health Information Technology Limited's (HKG:241) Price
Sep 28Alibaba Health Information Technology Limited's (HKG:241) Intrinsic Value Is Potentially 25% Below Its Share Price
Jul 02Is Alibaba Health Information Technology Limited (HKG:241) Potentially Undervalued?
Jun 11Estimating The Fair Value Of Alibaba Health Information Technology Limited (HKG:241)
Jun 22Is There An Opportunity With Alibaba Health Information Technology Limited's (HKG:241) 49% Undervaluation?
Dec 01Alibaba Health Information Technology (HKG:241) Is Looking To Continue Growing Its Returns On Capital
Oct 15Estimating The Fair Value Of Alibaba Health Information Technology Limited (HKG:241)
Aug 12Alibaba Health Information Technology (HKG:241) Is Doing The Right Things To Multiply Its Share Price
Jun 25These Analysts Just Made A Huge Downgrade To Their Alibaba Health Information Technology Limited (HKG:241) EPS Forecasts
May 30Earnings Report: Alibaba Health Information Technology Limited Missed Revenue Estimates By 6.8%
May 27The Return Trends At Alibaba Health Information Technology (HKG:241) Look Promising
Mar 23Should You Be Adding Alibaba Health Information Technology (HKG:241) To Your Watchlist Today?
Mar 05How Much Are Alibaba Health Information Technology Limited (HKG:241) Insiders Taking Off The Table?
Feb 15Are Alibaba Health Information Technology's (HKG:241) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Jan 31
If You Had Bought Alibaba Health Information Technology (HKG:241) Stock Three Years Ago, You Could Pocket A 457% Gain Today
Dec 31Has Alibaba Health Information Technology Limited's (HKG:241) Impressive Stock Performance Got Anything to Do With Its Fundamentals?
Dec 16Will Alibaba Health Information Technology's (HKG:241) Growth In ROCE Persist?
Dec 01CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Mar 31 2024 | CN¥7m | CN¥2m | CN¥883m |
| Dec 31 2023 | n/a | n/a | CN¥851m |
| Sep 30 2023 | n/a | n/a | CN¥817m |
| Jun 30 2023 | n/a | n/a | CN¥675m |
| Mar 31 2023 | CN¥6m | CN¥1m | CN¥536m |
| Dec 31 2022 | n/a | n/a | CN¥332m |
| Sep 30 2022 | n/a | n/a | CN¥128m |
| Jun 30 2022 | n/a | n/a | -CN¥69m |
| Mar 31 2022 | CN¥6m | CN¥1m | -CN¥266m |
| Dec 31 2021 | n/a | n/a | -CN¥216m |
| Sep 30 2021 | n/a | n/a | -CN¥167m |
| Jun 30 2021 | n/a | n/a | CN¥91m |
| Mar 31 2021 | n/a | n/a | CN¥349m |
| Dec 31 2020 | n/a | n/a | CN¥313m |
| Sep 30 2020 | n/a | n/a | CN¥278m |
| Jun 30 2020 | n/a | n/a | CN¥136m |
| Mar 31 2020 | CN¥12m | CN¥2m | -CN¥7m |
| Dec 31 2019 | n/a | n/a | -CN¥3m |
| Sep 30 2019 | n/a | n/a | CN¥1m |
| Jun 30 2019 | n/a | n/a | -CN¥40m |
| Mar 31 2019 | CN¥7m | CN¥33k | -CN¥82m |
Tazminat ve Piyasa: Difan 'nin toplam tazminatı ($USD 951.23K ), Hong Kong pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 576.36K ).
Tazminat ve Kazançlar: Difan 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.
CEO
Difan Shen (46 yo)
less than a year
Görev süresi
CN¥6,814,000
Tazminat
Mr. Difan Shen serves as Chief Executive Officer of Alibaba Health Information Technology Limited from November 28, 2023 and serves as Executive Director since October 13, 2021. He was Chief Operating Offi...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO & Executive Director | less than a year | CN¥6.81m | 0.0089% HK$ 6.2m | |
| CFO & Executive Director | 4.6yrs | CN¥5.34m | 0.0050% HK$ 3.5m | |
| Legal Counsel & Joint Company Secretary | 1.8yrs | Veri yok | Veri yok | |
| Chief Marketing Officer | 2.7yrs | Veri yok | Veri yok | |
| Chief People Officer | 4.8yrs | Veri yok | Veri yok | |
| Financial Controller | no data | Veri yok | Veri yok | |
| Chief Legal Advisor & Joint Company Secretary | 1.3yrs | Veri yok | Veri yok |
2.3yrs
Ortalama Görev Süresi
Deneyimli Yönetim: 241 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.3 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO & Executive Director | 3.1yrs | CN¥6.81m | 0.0089% HK$ 6.2m | |
| CFO & Executive Director | 4.1yrs | CN¥5.34m | 0.0050% HK$ 3.5m | |
| Independent Non-Executive Director | 1.3yrs | CN¥411.00k | Veri yok | |
| Independent Non-Executive Director | 5.4yrs | CN¥348.00k | Veri yok | |
| Non-Executive Chairman of the Board | 4.7yrs | CN¥19.00m | 0.0086% HK$ 6.0m | |
| Independent Non-Executive Director | 1.3yrs | CN¥223.00k | Veri yok | |
| Non-Executive Director | 1.5yrs | Veri yok | Veri yok | |
| Non-Executive Director | 1.1yrs | Veri yok | Veri yok |
2.3yrs
Ortalama Görev Süresi
48.5yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: 241 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 2.3 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.